MS
Wanna Know Why Drug Discovery/Development Is Hard?
FTY270 (fingolimod), an S1P1 modulator, is a T-cell specific immunosuppressant and is a hot, emerging phase III therapy for MS from Novartis (NVS). So where is the difficulty?
In the Aug. 14, 2008, issue of Nature, scientists from Emory University and the Yerkes Primate Research Center reported that, paradoxically, in a mouse model the drug [...]
TEVA Gets Taste of Own Medicine
The Israeli generic drug maker, known for its aggressive tactics is getting a taste of its own medicine if Pittsburgh based, Mylan has anything to say about it (I can’t get enough of the: “taste of its own medicine line”).
TEVA markets a proprietary, branded drug for MS called glatiramer acetate (COPAXONE), sold $1.7B worth of [...]
Fampridine Results Send Acorda Up +20%
Acorda Therapeutics announced positive results from its second Phase 3 clinical trial of Fampridine-SR on walking ability in people with multiple sclerosis (MS). In a timed, 25 foot walk test, just under half of the patients showed improved walking speed vs. placebo. Acorda plans to submit an NDA in 2009.
This was an interesting endpoint. [...]
Disease Briefing: Multiple Sclerosis
All this talk of MS in the last week has made your editor hungry for some MS info-video-graphic.
MS News: Fingolimod (FTY720) Open Label Results and Tysabri PML Data
Last night (and I doubt coincidentally) two promising therapies for MS released positive data. Novartis’s fingolimod (FTY720) in a Phase II study extension showed 68-73% of patients with multiple sclerosis remained relapse-free after three years of treatment and that 89% of patients free from active brain lesions - the injury caused by [...]
Recent Comments